Focus on ALS and TBI

Thera is a biotechnology company dedicated to the discovery, development and commercialization of impactful therapeutic interventions for neurodegenerative disorders.

Our regenerative molecules and RNA-based compounds are therapeutics potentially disease-modifying for a fatal disease, Amyotrophic Lateral Sclerosis (ALS), and a severely disabling condition, Traumatic Brain Injury (TBI).

Competitive Advantage

Thera Neuropharma is advancing an innovative approach that employs two complementary technologies.

Our small molecule regenerative therapy (SMRT) and self-delivering RNA interference (sd-rxRNA®) technology platforms are uniquely positioned to modulate cell functioning, regenerative processes, and RNA activity in the central nervous system.

The lead candidates leverage the activation of a key CNS pathway and modulate cell energy mechanisms. These molecules maintain brain cell viability and regenerate the brain network with a potentially disease-modifying and curative effect.


May 09, 2016 – Thera Neuropharma Awarded Funding from Flemish Agency For Innovation & Entrepeneurship.

May 03, 2016 – Thera Neuropharma licenses SOD1 sd-rxRNA® platform technology from RXi.

Thera Neuropharma opens a European affiliate in Belgium.
The company will focus on discovery and translational activities to further the development of the ALS program.